Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Endoscopic Therapy of Malignant Bile Duct Strictures

This study has been terminated.
(Lack of enrollment)
Sponsor:
Information provided by (Responsible Party):
William R. Brugge, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01543607
First received: February 15, 2012
Last updated: March 13, 2017
Last verified: March 2017
Results First Received: March 13, 2017  
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: No masking;   Primary Purpose: Treatment
Conditions: Obstruction of Biliary Tree
Biliary Tract Cancer
Biliary Tract Neoplasms
Intervention: Device: Radiofrequency ablation catheter (Habib EndoHBP)

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Treatment

Radiofrequency ablation catheter

Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct


Participant Flow:   Overall Study
    Treatment
STARTED   1 
COMPLETED   1 
NOT COMPLETED   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Treatment

Radiofrequency ablation catheter

Radiofrequency ablation catheter (Habib EndoHBP): Catheter placement into bile duct


Baseline Measures
   Treatment 
Overall Participants Analyzed 
[Units: Participants]
 1 
Age 
[Units: Participants]
Count of Participants
 
<=18 years      0   0.0% 
Between 18 and 65 years      0   0.0% 
>=65 years      1 100.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
 
Female      1 100.0% 
Male      0   0.0% 
Region of Enrollment 
[Units: Participants]
 
United States   1 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Safety: Number of Bile Leak After RFA Procedure   [ Time Frame: 2 years ]

2.  Secondary:   Feasibility: Ease of the Radiofrequency Ablation Catheter Placement   [ Time Frame: 2 years ]

3.  Secondary:   Effectiveness: Change From Baseline in Bile Duct Diameter.   [ Time Frame: 2 years ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: William R. Brugge
Organization: Mass. General Hospital
phone: 617-724-0578
e-mail: wbrugge@partners.org



Responsible Party: William R. Brugge, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01543607     History of Changes
Other Study ID Numbers: 11-405
Study First Received: February 15, 2012
Results First Received: March 13, 2017
Last Updated: March 13, 2017